Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
Letters

Perspectives on drug withdrawals

Russell Williams
CMAJ July 19, 2005 173 (2) 129-129-a; DOI: https://doi.org/10.1503/cmaj.1050027
Russell Williams
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

It was with disappointment that I read the CMAJ editorial on the withdrawal of rofecoxib (Vioxx).1 In particular, I am disappointed with the narrow perspective on the safety of our industry's medicines and the supposed conflict caused by a relationship between industry and Health Canada.

The member companies of Rx&D (Canada's Research-Based Pharmaceutical Companies) are committed to patients, to their health and well-being, and to the assurance that new medicines are as safe and efficacious as humanly and scientifically possible. No company wants to launch a medicine on the market to have it withdrawn at some future date. The impact for the company, in terms of both reputation and financial perspective, can be devastating. That is why any negative effect experienced by patients in the development phase of a medicine must be reported. Once a medication is made available to patients, any serious and unexpected adverse effects reported to the manufacturer must, in turn, be reported to Health Canada within 15 days.

When should a medicine be allowed to go to market? Once all possible combinations with other drugs or commonly used products have been studied? For many patients, this is not an option. Who would have thought a few years ago that grapefruit juice could have a dramatic impact on the health of patients taking certain types of medicines? Yet pharmacists now alert their patients to potential interactions between grapefruit juice and medications.2 Patients who take medicines must understand that any pharmaceutical chemical introduced into the body is not natural; hence, they should, with the consultation and supervision of their physician, weigh concerns against benefits and make an informed decision.

Reference to potential conflict caused by an emphasis on Health Canada's “partnerships with industry” is simply not true.

When taken appropriately, medicines can provide positive health outcomes and value to patients, their families, our health care system and society as a whole.

References

  1. 1.↵
    Vioxx: lessons for Health Canada and the FDA [editorial]. CMAJ 2005;172(1):5.
    OpenUrlFREE Full Text
  2. 2.↵
    Maskalyk J. Grapefruit juice: potential drug interactions. CMAJ 2002;167(3):279-80.
    OpenUrlFREE Full Text
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 173 (2)
CMAJ
Vol. 173, Issue 2
19 Jul 2005
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Perspectives on drug withdrawals
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Perspectives on drug withdrawals
Russell Williams
CMAJ Jul 2005, 173 (2) 129-129-a; DOI: 10.1503/cmaj.1050027

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Perspectives on drug withdrawals
Russell Williams
CMAJ Jul 2005, 173 (2) 129-129-a; DOI: 10.1503/cmaj.1050027
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The 5 Ps need an update: toward a comprehensive sexual history
  • Don’t ignore perimenopause
  • Hospital-at-home programs in Canada: challenges and pitfalls
Show more Letters

Similar Articles

Collections

  • Topics
    • Canadian government
    • Drugs: gastrointestinal system

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire